WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101
March 16, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials
February 24, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD" or the “Company”) today announced that it has signed an agreement with CNS...
WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study
February 18, 2021 09:05 ET
|
WPD Pharmaceuticals
WPD Pharmaceuticals plans to initiate a Berubicin Phase 2 adult GBM trial in the first half of 2021 and a multicenter pediatric malignant glioma Phase 1 clinical trial in 2021 CNS...
WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Further Support on Berubicin Trials
February 11, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Announces US$1.5M Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin
February 09, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company is pleased to announce...
WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug
February 05, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Feb. 05, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals to Participate in the 7ᵗʰ Annual LSX World Congress, a Leading Global Healthcare and Life Sciences Forum
January 28, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 28, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Contracts Clinigen Clinical Supplies Management to Perform QP Certification of Berubicin for the Clinical Trials Authorization
January 14, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 14, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals to Collaborate With IAG to Deploy Artificial Intelligence and Quantitative Imaging to Assess the Effects of Berubicin
January 06, 2021 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Jan. 06, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to...
WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada
October 26, 2020 07:30 ET
|
WPD Pharmaceuticals
VANCOUVER, British Columbia, Oct. 26, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to provide...